Profile data is unavailable for this security.
About the company
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
- Revenue in GBP (TTM)0.00
- Net income in GBP-2.70m
- Incorporated2007
- Employees67.00
- LocationCizzle Biotechnology Holdings PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
- Phone+44 207 469 0930
- Fax+44 238 123 0382
- Websitehttps://cizzlebiotechnology.com/